Trial Profile

An Open-Label Phase 1/2 Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldoxorubicin (Primary) ; Ifosfamide; Mesna
Indications Chondrosarcoma; Ewing's sarcoma; Gastrointestinal stromal tumours; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
Focus Adverse reactions
Sponsors CytRx Corporation; LadRx Corporation

27 Jan 2022 Status changed from recruiting to completed.
07 Jun 2018 According to a CytRx Corporation media release, pooled data from this and other study (700214726) were presented at the American Society of Clinical Oncology 2018 Annual Meeting.
07 Jun 2018 Results presented in the CytRx Corporation media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com